日本批准Dupixent治疗成年球状皮虫,这是这种罕见的水泡病的首个有针对性的疗法. Japan approves Dupixent for adult bullous pemphigoid, the first targeted therapy for the rare blistering disease.

由赛诺菲和Regeneron开发的Dupixent (dupilumab) 在日本获得批准,作为第一个针对性治疗用于患有囊型皮质炎的成年人. 这是一种罕见的自身免疫性皮肤疾病,特征是水泡形成. Dupixent (dupilumab), developed by Sanofi and Regeneron, has received approval in Japan as the first targeted therapy for adults with bullous pemphigoid, a rare autoimmune skin disease characterized by blistering. 批准标志着治疗选择的重大进步,提供精准医学方法以减少疾病严重性和改善患者结果. The approval marks a significant advancement in treatment options, offering a precision medicine approach aimed at reducing disease severity and improving patient outcomes.